Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
GTH POWR Grades
- Sentiment is the dimension where GTH ranks best; there it ranks ahead of 68.69% of US stocks.
- GTH's strongest trending metric is Stability; it's been moving down over the last 47 weeks.
- GTH's current lowest rank is in the Momentum metric (where it is better than 16.43% of US stocks).
GTH Stock Summary
- GTH's went public 1.25 years ago, making it older than just 1.35% of listed US stocks we're tracking.
- GTH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 0.82% of US stocks.
- Genetron Holdings Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -117.48%, greater than the shareholder yield of just 1.73% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Genetron Holdings Ltd are DOOO, ALIM, CLRO, POLA, and SRTS.
- To check out Genetron Holdings Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001782594.
GTH Stock Price Chart Interactive Chart >
GTH Price/Volume Stats
| Current price | $16.46 | 52-week high | $31.54 |
| Prev. close | $16.39 | 52-week low | $9.03 |
| Day low | $16.22 | Volume | 2,096,800 |
| Day high | $16.94 | Avg. volume | 349,263 |
| 50-day MA | $15.23 | Dividend yield | N/A |
| 200-day MA | $19.13 | Market Cap | 1.46B |
Genetron Holdings Ltd. ADR (GTH) Company Bio
Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.
Latest GTH News From Around the Web
Below are the latest news stories about Genetron Holdings Ltd that investors may wish to consider to help them evaluate GTH as an investment opportunity.
Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has partnered with a consortium of 14 top Chinese hospitals to release 13 key research findings at the ESMO 2021 Congress, hosted by the European Society for Medical Oncology. The fi |
Genetron Added to FTSE Russell Global Equity Index SeriesBEIJING, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), today announced that Genetron will be added to the below FTSE Global Equity Index Series ("GEIS"), following FTSE''s most recent quarterly review. These inclusions will become effective after the market close on Friday, September 17, 2021: |
Genetron Healths Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021. Awarded by the Gertrud Reemtsma Foundation through the Max Planck Society, the prize is one of the most prominent awards in neuroscience and recognizes individuals who have made outstanding and original contributions to the understanding of neurobiology and neurological disease. The ceremony took place at the Max-Planck-Institute in Cologne, Germany, on A... |
Genetron Health’s Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021. Awarded by the Gertrud Reemtsma Foundation through the M |
Does This Valuation Of Genetron Holdings Limited (NASDAQ:GTH) Imply Investors Are Overpaying?In this article we are going to estimate the intrinsic value of Genetron Holdings Limited ( NASDAQ:GTH ) by projecting... |
GTH Price Returns
| 1-mo | 37.28% |
| 3-mo | -22.21% |
| 6-mo | -12.54% |
| 1-year | 43.88% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 17.57% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...